I am excited to announce that Lirio, the world leader in personalized behavior modification through Precision Nudging®, is our latest partner to join the BrightInsight Ecosystem.
Drug companion apps have the potential to improve patient outcomes. From getting patients on the appropriate therapy faster, to increasing adherence and ultimately persistence, to more accurate self-administration of therapies, these apps can make a world of impact.
Despite the potential, demonstrating meaningful impact to outcomes from companion apps and other digital health solutions has historically been challenging. Most recently, the Peterson Health Technology Institute (PHTI) roiled the digital health space with a report evaluating digital diabetes management tools that showed the technologies "do not deliver meaningful clinical benefits, and they increase healthcare spending relative to usual care."
Many industry experts disagreed with aspects of the report, but Brian Dolan, editor at Exits & Outcomes, shared this salient anecdote: "The more appropriate conclusion for Peterson’s report is that the evidence is — as always in digital health — too thin."
BrightInsight agrees. Meeting patients where they are on their treatment journey requires robust, smart technology to ensure patients aren’t experiencing a "one-size-fits-all" app. Changing people’s behavior is hard. Understanding why people behave the way they do is the key to removing barriers and supporting people on the pathway to change.
Lirio understands how to influence human behavior. As the only AI Platform that engages consumers and learns what motivates them and what influences their decisions, Lirio can move patients along their unique journeys to better health through person-centered communication.
By integrating Lirio’s Intelligence capabilities into our BrightInsight Platform, BrightInsight can enhance their life sciences customers’ patient companion apps to catalyze patient behavior change, ultimately leading to improved outcomes.
Specifically, BrightInsight and Lirio can identify key engagement and personalization opportunities for a specific brand and create a hyper-personalized experience for companion app users. This integration will enable biopharma brands to deliver next-best nudges to drive sustained engagement, adherence, and behavior change across a complex set of medications and use cases.
Lirio’s Platform has consistently changed behavior across chronic conditions, preventative care, clinical trials recruitment, employee benefits utilization, and more. In addition, Lirio’s Precision Nudging has demonstrated a positive ROI for healthcare organizations across multiple health behaviors and conditions. Specifically, Lirio’s Precision Nudging for Diabetes resulted in over 60% of chronically disengaged patients with Type 1 or Type 2 diabetes completing at least one diabetes-focused primary care visit. Lirio’s solution also boosted the adoption of RSV vaccine by a national retail pharmacy chain, outperforming standard pharmacy messaging by 35%. Lastly, Lirio has demonstrated that their n=1 approach to patient engagement helps address health inequities, providing comparable outcomes across racial and ethnic groups, income levels, and educational attainment.
This partnership represents a huge opportunity to enhance the patient journey. For conditions such as inflammatory diseases, diabetes, hypertension, obesity, mental health disorders and more, effective behavioral interventions are critical for successful disease management. Personalized behavioral health solutions are also often required to sustain long-term patient adherence and persistence to treatment plans.
"At Lirio, we have seen first-hand where compelling digital health apps fail to retain users or fall short of actually improving outcomes," says Lirio’s CEO, Marten den Haring. "Using our Precision Nudging technology, we can supercharge the patient companion apps that BrightInsight is building to sustain behavior change and achieve significant outcome improvement."
We welcome Lirio to the BrightInsight Ecosystem, a network of more than 20 of the world’s leading healthcare and technology companies collaborating to drive digital health innovation, adoption, and engagement. By integrating with Lirio’s innovative platform, BrightInsight can deliver truly patient-centric behavioral health experiences for our life sciences customers.